<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>150(3)</volume><submitter>Wu R</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment.&lt;h4>Method&lt;/h4>Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method.&lt;h4>Results&lt;/h4>TGM1 is expressed differe</pubmed_abstract><journal>Journal of cancer research and clinical oncology</journal><pagination>123</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10933153</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer.</pubmed_title><pmcid>PMC10933153</pmcid><pubmed_authors>Han P</pubmed_authors><pubmed_authors>Chen K</pubmed_authors><pubmed_authors>Miyamoto A</pubmed_authors><pubmed_authors>Li D</pubmed_authors><pubmed_authors>Wu R</pubmed_authors><pubmed_authors>Yoo KH</pubmed_authors><pubmed_authors>Feng D</pubmed_authors><pubmed_authors>Wei W</pubmed_authors><pubmed_authors>Zhang S</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Tuo Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer.</name><description>&lt;h4>Background&lt;/h4>There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment.&lt;h4>Method&lt;/h4>Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method.&lt;h4>Results&lt;/h4>TGM1 is expressed differe</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-04-25T03:28:41.774Z</modification><creation>2026-04-25T03:22:24.86Z</creation></dates><accession>S-EPMC10933153</accession><cross_references><pubmed>38472489</pubmed><doi>10.1007/s00432-024-05640-6</doi></cross_references></HashMap>